Start Date
August 1, 2019
Primary Completion Date
August 1, 2019
Study Completion Date
August 1, 2019
Otoband
Participants during infusion following chemotherapy will wear the Otoband set at normal power (effective) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
Placebo device
Participants during infusion following chemotherapy will wear the placebo device set at low power (6 decibels lower than normal power, ineffective power) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
I. Brodsky Associates Outpatient Hematology & Oncology Clinic, Philadelphia
Lead Sponsor
Drexel University College of Medicine
OTHER
Otolith Labs
INDUSTRY